HAVN Life Sciences Inc.

Equities

HAVN

CA4196213058

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 02:12:37 2023-11-09 pm EST 5-day change 1st Jan Change
0.03 CAD -.--% Intraday chart for HAVN Life Sciences Inc. +20.00% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HAVN Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023 CI
HAVN Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022 CI
HAVN Life Sciences Inc. Announces Retail Listing with Loblaws Company Ltd CI
HAVN Life Sciences Inc. Announces Board Changes CI
HAVN Life Sciences Inc. Announces CFO Changes CI
Havn Life Sciences Inc. Announces Departure of Mr. Tim Laidler as A Director CI
HAVN Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022 CI
HAVN Life Sciences Says Board Putting Together Restructuring Plan MT
HAVN Life Sciences Inc. Auditor Raises 'Going Concern' Doubt CI
HAVN Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2022 CI
HAVN Life Sciences Completes First Tranche of Financing Commitment by Alpha Blue Ocean, Reports Warrant Amendments MT
HAVN Life to Undertake Share Consolidation MT
HAVN Life Shares Down 8.3% as Details $9 Million Financing Arrangement MT
HAVN Life Sciences Inc. announced that it expects to receive CAD 9 million in funding from Alpha Blue Ocean Investment Group CI
HAVN Life Sciences Inc. Enters Supply Agreement with MPB Group Inc CI
HAVN Life Sciences Inc. Announces Board Changes CI
HAVN Life Signs Supply Agreement with Licenced Jamaican Cannabis Producer, Green Stripe Naturals MT
HAVN Life Sciences Inc. Signs Supply Agreement with Licenced Jamaican Cannabis Producer, Green Stripe Naturals Ltd CI
HAVN Life Sciences Inc. Secures Supply Agreement with Atman Retreats CI
HAVN Life Ships First Order of Natural Health Products to Australia's Woke Pharmaceuticals MT
Havn Life Ships First White Label Order to Distribution Partner Woke Pharmaceuticals in Australia CI
HAVN Life Sciences Inc. Launches the Brain Evolve Series CI
HAVN Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2022 CI
HAVN Life Sciences Inc. Expands Supply Agreement with Mycotopia Therapies Inc CI
HAVN Life Announces Distribution Deal with Jonluca Enterprises Inc CI
Chart HAVN Life Sciences Inc.
More charts
HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the scientific research and development of psychopharmacological and natural health care products. It is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatments to support brain health and enhance the capabilities of the mind. The Company has two business divisions: HAVN Labs and HAVN Retail. The HAVN Labs division is engaged in the development of research protocols to cover the production of Psilocybe spp. Through its research division, HAVN Labs, it has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research. The HAVN Retail division formulates and sells natural health products (NHPs) using compounds. It offers a full range of mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
More about the company
  1. Stock Market
  2. Equities
  3. HAVN Stock
  4. News HAVN Life Sciences Inc.
  5. HAVN Life Sciences Says Board Putting Together Restructuring Plan